AR064010A1 - Inhibidores de la actividad de la akt - Google Patents

Inhibidores de la actividad de la akt

Info

Publication number
AR064010A1
AR064010A1 ARP070105281A ARP070105281A AR064010A1 AR 064010 A1 AR064010 A1 AR 064010A1 AR P070105281 A ARP070105281 A AR P070105281A AR P070105281 A ARP070105281 A AR P070105281A AR 064010 A1 AR064010 A1 AR 064010A1
Authority
AR
Argentina
Prior art keywords
aob
alkyl
cycloalkyl
heterocyclyl
aryl
Prior art date
Application number
ARP070105281A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR064010A1 publication Critical patent/AR064010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

La presente proporciona compuestos de naftiridina sustituidos que inhiben la actividad de la Akt. En particular, los compuestos descritos inhiben de manera selectiva una o dos de las isoformas de la Akt. También proporciona composiciones que comprenden tales compuestos inhibidores y procedimientos de inhibicion de la actividad de la Akt mediante la administracion del compuesto a un paciente en necesidad de tratamiento de cáncer. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en la que: a es 0 o 1; b es 0 o 1; m es 0, 1 o 2; p es 0, 1 o 2; R2 se selecciona independientemente entre alquilo C1-6, alcoxi C1-6, CO2H, halo, OH y NH2; el anillo Y es cicloalquilo C4-7; R1 se selecciona entre: H, oxo, (C=O)aOb-alquilo C1-10, (C=O)aOb-arilo, (C=O)aOb-alquenilo C2-10, (C=O)aOb-alquinilo C2-10, CO2H, halo, OH, Ob perfluoroalquilo C1-6, (C=O)aNR7R8, CN, (C=O)aOb cicloalquilo C3-8, S(O)mNR7R8, SH, S(O)m-alquilo C1-10 y (C=O)aOb-heterociclilo, dicho alquilo, arilo, alquenilo, alquinilo, cicloalquilo, y heterociclilo está opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6 es; R6 es (C=O)aOb-alquilo C1-10, (C=O)aOb-arilo, alquenilo C2-10, alquinilo C2-10, (C=O)aOb-heterociclilo, CO2H, halo, OH, Ob perfluoroalquilo C1-6, Oa(C=O)bNR7R8, oxo, CHO, (N=O)R7R8, S(O)mNR7R8, SH, S(O)m-alquilo C1-10 o (C=O)aOb-cicloalquilo C3-8, dicho alquilo, arilo, alquenilo, alquinilo, heterociclilo, y cicloalquilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6a; R6a se selecciona entre (C=O)aOb alquilo C1-10, Oa perfluoroalquilo C1-3, alquileno C0-6, -S(O)mRa, SH, oxo, OH, halo, CN, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-6, alquileno C0-6-arilo, alquileno C0- 6-heterociclilo, alquilen C0-6-N(Rb)2, C(O)Ra, alquilen C0-6-CO2Ra, C(O)H, y alquilen C0-6-CO2H, dicho alquilo, alquenilo, alquinilo, cicloalquilo, arilo, y heterociclilo está opcionalmente sustituido con uno a tres sustituyentes seleccionados entre Rb, OH, alcoxi C1-6, halogeno, CO2H, CN, Oa(C=O)b alquilo C1-6, oxo, y N(Rb)2, R7 y R8 se seleccionan independientemente entre: H, (C=O)aOb alquilo C1-10, (C=O)aOb cicloalquilo C3-8, (C=O)aOb-arilo, (C=O)aOb-heterociclilo, alquenilo C2-10, alquinilo C2-10, SH, SO2Ra, y (C=O)aNRb2, dicho alquilo, cicloalquilo, arilo, heterociclilo, alquenilo, y alquinilo está opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6a, o R7 y R8 se pueden tomar juntos con el nitrogeno al que están unidos para formar a heterociclo monocíclico o bicíclico con 3-7 miembros en cada anillo conteniendo opcionalmente, además del nitrogeno, uno o dos heteroátomos adicionales seleccionados entre N, O y S, dicho heterociclo monocíclico o bicíclico opcionalmente sustituido con uno o más sustituyentes seleccionados entre R6a; Ra es alquilo C1-6, cicloalquilo C3-6, arilo, o heterociclilo; y Rb es independientemente: H, alquilo C1-6, arilo, heterociclilo, cicloalquilo C3-6, (C=O)aOb alquilo C1-6, o S(O)mRa; o una sal o estereoisomero farmacéuticamente aceptable de los mismos.
ARP070105281A 2006-12-06 2007-11-28 Inhibidores de la actividad de la akt AR064010A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87319806P 2006-12-06 2006-12-06
US88066107P 2007-01-16 2007-01-16
US96787207P 2007-09-06 2007-09-06

Publications (1)

Publication Number Publication Date
AR064010A1 true AR064010A1 (es) 2009-03-04

Family

ID=39492823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105281A AR064010A1 (es) 2006-12-06 2007-11-28 Inhibidores de la actividad de la akt

Country Status (30)

Country Link
US (3) US7576209B2 (es)
EP (1) EP2104669B1 (es)
JP (2) JP4431636B1 (es)
KR (1) KR101110598B1 (es)
CN (1) CN101600706B (es)
AR (1) AR064010A1 (es)
AU (1) AU2007328286B2 (es)
BR (1) BRPI0719580A2 (es)
CA (1) CA2670760C (es)
CL (1) CL2007003495A1 (es)
CO (1) CO6190528A2 (es)
CR (1) CR10851A (es)
EA (1) EA016195B1 (es)
EC (1) ECSP099376A (es)
ES (1) ES2527567T3 (es)
GE (1) GEP20125469B (es)
GT (1) GT200900146A (es)
HK (1) HK1137758A1 (es)
HN (1) HN2009001112A (es)
IL (2) IL198826A (es)
MA (1) MA31027B1 (es)
MX (1) MX2009006052A (es)
NI (1) NI200900106A (es)
NO (1) NO20092569L (es)
NZ (2) NZ577470A (es)
PE (1) PE20081341A1 (es)
SV (1) SV2009003283A (es)
TN (1) TN2009000224A1 (es)
TW (1) TWI386410B (es)
WO (2) WO2008070016A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610888C (en) * 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibitors of akt activity
AU2007327992A1 (en) * 2006-12-06 2008-06-12 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
MX2010013224A (es) * 2008-06-03 2010-12-21 Merck Sharp & Dohme Inhibidores de la actividad de la serina/treonina cinasa.
EP2303269B1 (en) * 2008-06-03 2014-07-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2307422B1 (en) 2008-07-04 2014-03-26 Msd K.K. Novel spirochromanone carboxylic acids
ES2797955T3 (es) * 2008-08-25 2020-12-04 Novartis Ag Moduladores de la ruta de hedgehog
DE102008043724A1 (de) * 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein
US20110288090A1 (en) * 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
EP2405756B1 (en) 2009-03-12 2013-07-03 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2011029802A1 (en) 2009-09-08 2011-03-17 F. Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
CN103097384B (zh) 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
WO2012007416A1 (en) 2010-07-13 2012-01-19 Bayer Pharma Aktiengesellschaft Bicyclic pyrimidines
JP5926727B2 (ja) * 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
ES2549443T3 (es) * 2010-12-16 2015-10-28 Bayer Intellectual Property Gmbh Pirimido[1,2-b]indazoles sustituidos y su uso como moduladores de la ruta de PI3K/AKT
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
SG193327A1 (en) 2011-04-06 2013-10-30 Taiho Pharmaceutical Co Ltd Novel imidazo-oxazine compound or salt thereof
ME02316B (me) * 2011-04-07 2016-06-20 Bayer Ip Gmbh Imidazopiridazini kao inhibitori akt kinaze
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2860724A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
JP6088542B2 (ja) 2012-01-10 2017-03-01 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換イミダゾピラジン類
WO2013109876A1 (en) 2012-01-20 2013-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
RU2618423C2 (ru) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP4265300A3 (en) 2013-10-01 2023-11-29 Novartis AG Combination
US20160235714A1 (en) 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
WO2015094928A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Liposomal compositions for allosteric akt inhibitors
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
CA2942204A1 (en) 2014-03-12 2015-09-17 Novartis Ag Combination comprising a btk inhibitor and an akt inhibitor
ES2872552T3 (es) * 2014-03-17 2021-11-02 Merck Sharp & Dohme Nanopartículas poliméricas y métodos de preparación y de uso de las mismas
CN107428779A (zh) 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3372601B1 (en) * 2015-10-22 2022-09-21 Mitsubishi Tanabe Pharma Corporation Novel bicyclic heterocyclic compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108426971B (zh) * 2018-03-09 2020-03-20 浙江中一检测研究院股份有限公司 一种快速检测水中微囊藻毒素的方法
IL297596A (en) * 2020-05-08 2022-12-01 Georgiamune Llc Modulators of akt3 and methods of using them

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527531A (ja) * 2001-04-10 2004-09-09 メルク　エンド　カムパニー　インコーポレーテッド 癌を治療する方法
WO2002083138A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
DE60336576D1 (de) 2002-10-30 2011-05-12 Merck Sharp & Dohme Hemmer der akt aktivität
CA2522430A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
DE602004026047D1 (de) 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
EP1631548B1 (en) 2003-04-24 2009-10-28 Merck & Co., Inc. Inhibitors of akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
TWI344961B (en) * 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1824849A4 (en) * 2004-12-02 2009-09-30 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
CN101242834A (zh) 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
CA2597456A1 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
JP2008535915A (ja) * 2005-04-12 2008-09-04 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
CA2610888C (en) 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibitors of akt activity
CA2636043A1 (en) * 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
CA2682504C (en) * 2007-04-05 2012-10-30 Amgen Inc. Aurora kinase modulators and method of use

Also Published As

Publication number Publication date
MA31027B1 (fr) 2009-12-01
US20090253734A1 (en) 2009-10-08
CA2670760C (en) 2012-01-24
EA200970542A1 (ru) 2009-12-30
ES2527567T3 (es) 2015-01-26
CN101600706A (zh) 2009-12-09
EP2104669A2 (en) 2009-09-30
ECSP099376A (es) 2009-07-31
AU2007328286A2 (en) 2009-08-06
CL2007003495A1 (es) 2008-05-30
NI200900106A (es) 2010-01-20
CN101600706B (zh) 2013-10-16
US20080161317A1 (en) 2008-07-03
NZ577470A (en) 2011-11-25
CO6190528A2 (es) 2010-08-19
EA016195B1 (ru) 2012-03-30
EP2104669B1 (en) 2014-10-15
IL198826A (en) 2010-11-30
TN2009000224A1 (en) 2010-10-18
HK1137758A1 (en) 2010-08-06
JP5364454B2 (ja) 2013-12-11
IL205220A0 (en) 2011-07-31
KR20090086095A (ko) 2009-08-10
NZ595829A (en) 2013-04-26
TWI386410B (zh) 2013-02-21
KR101110598B1 (ko) 2012-03-08
AU2007328286A1 (en) 2008-06-12
HN2009001112A (es) 2011-07-22
CA2670760A1 (en) 2008-06-12
MX2009006052A (es) 2009-06-17
BRPI0719580A2 (pt) 2013-12-17
TW200831509A (en) 2008-08-01
WO2008070041A3 (en) 2008-08-28
GT200900146A (es) 2010-04-13
WO2008070016A3 (en) 2008-09-12
AU2007328286B2 (en) 2011-01-20
NO20092569L (no) 2009-07-06
GEP20125469B (en) 2012-04-10
JP2009298786A (ja) 2009-12-24
WO2008070016A2 (en) 2008-06-12
US7576209B2 (en) 2009-08-18
CR10851A (es) 2009-06-25
US8288407B2 (en) 2012-10-16
WO2008070041A2 (en) 2008-06-12
PE20081341A1 (es) 2008-10-19
JP2010511703A (ja) 2010-04-15
US20110160183A1 (en) 2011-06-30
SV2009003283A (es) 2009-11-09
JP4431636B1 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
AR064010A1 (es) Inhibidores de la actividad de la akt
AR060619A1 (es) Triazoloquinazolinonas como inhibidores de las quinasas de punto de control
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR045342A1 (es) Inhibidores de quinesina mitotica
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR084507A1 (es) Derivados de indazoliltriazol
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR068466A1 (es) Cianoisoquinolina
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
AR061804A1 (es) Inhibidores de tirosina quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR054484A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
CO6351734A2 (es) Compuestos de amida utiles en terapia

Legal Events

Date Code Title Description
FG Grant, registration